Non-small cell lung cancer

News

Akeso's ivonescimab extends survival in PD-L1+ lung cancer

Akeso's PD-1xVEGF drug ivonescimab improves survival in another late-stage Chinese trial, ahead of a key international study readout later this year.

News

Image of a woman awaiting treatment in hospital

UK patient first in world to get novel lung cancer vaccine

A woman from the Wirral in the UK has become the first patient in the world to receive an experimental, personalised lung cancer vaccine.

News

Nuvalent buy delivers new cancer approval for GSK

GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.

News

AstraZeneca adds another Chinese asset, from Dizal

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.

News

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

Akeso's ivonescimab extends survival in PD-L1+ lung cancer

UK patient first in world to get novel lung cancer vaccine

Nuvalent buy delivers new cancer approval for GSK

AstraZeneca adds another Chinese asset, from Dizal

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Roche's KRAS drug tops its rivals in lung cancer trial

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks